Drugs in development · updated 5 November 2026
UVADEX: clinical trials and development status
Other names and codes: methoxsalen, Oxsoralen-Ultra, Oxsoralen
As of 5 November 2026 UVADEX is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 11 diseases. The most advanced phase is II.
Summary updated every week · data as of 5 November 2026. In Phuturdex you can follow UVADEX and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Colitis | II | 1 | NCT07619898 |
| Connective tissue disease | II | 1 | NCT04986605 |
| Cutaneous T cell lymphoma | II | 1 | NCT05680558 |
| Diffuse scleroderma | II | 1 | NCT04986605 |
| Ewing sarcoma | II | 1 | NCT03778996 |
| Hepatitis | II | 1 | NCT07619898 |
| Melanoma | II | 1 | NCT07619898 |
| Mycosis fungoides | II | 1 | NCT05680558 |
| Sarcoma | II | 1 | NCT03778996 |
| Skin disease | II | 1 | NCT04986605 |
| Systemic scleroderma | II | 1 | NCT04986605 |
Everything on UVADEX
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 5 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.